These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37481825)

  • 1. The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis.
    Guo J; Sun Y; Liu G
    J Inorg Biochem; 2023 Oct; 247():112324. PubMed ID: 37481825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
    Lai YH; Kuo C; Kuo MT; Chen HHW
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
    Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of copper transporters in cisplatin resistance.
    Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
    Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming platinum drug resistance with copper-lowering agents.
    Chen HH; Kuo MT
    Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
    Zhao Q; Qi T
    Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
    Safaei R; Howell SB
    Crit Rev Oncol Hematol; 2005 Jan; 53(1):13-23. PubMed ID: 15607932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity.
    Bompiani KM; Tsai CY; Achatz FP; Liebig JK; Howell SB
    Metallomics; 2016 Sep; 8(9):951-62. PubMed ID: 27157188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
    Abada PB; Larson CA; Manorek G; Adams P; Howell SB
    Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lustrous insights into cisplatin accumulation: copper transporters.
    Kruh GD
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5807-9. PubMed ID: 14676099
    [No Abstract]   [Full Text] [Related]  

  • 11. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
    Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
    BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of copper transporters in the uptake and efflux of platinum containing drugs.
    Safaei R
    Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
    Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
    Kabolizadeh P; Ryan J; Farrell N
    Biochem Pharmacol; 2007 May; 73(9):1270-9. PubMed ID: 17234160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference between copper transport systems and platinum drugs.
    Arnesano F; Natile G
    Semin Cancer Biol; 2021 Nov; 76():173-188. PubMed ID: 34058339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of copper transporters in the development of resistance to Pt drugs.
    Safaei R; Holzer AK; Katano K; Samimi G; Howell SB
    J Inorg Biochem; 2004 Oct; 98(10):1607-13. PubMed ID: 15458823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin.
    Lasorsa A; Natile G; Rosato A; Tadini-Buoninsegni F; Arnesano F
    Curr Med Chem; 2018 Feb; 25(4):462-477. PubMed ID: 29121854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis in cancers: Function and implications from bench to bedside.
    Huang XY; Shen JY; Huang K; Wang L; Sethi G; Ma Z
    Biomed Pharmacother; 2024 Jul; 176():116874. PubMed ID: 38850661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
    Stojanovska V; McQuade R; Rybalka E; Nurgali K
    Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.